Patents by Inventor Randall T. Moon
Randall T. Moon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200009188Abstract: Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian subject in need thereof.Type: ApplicationFiled: September 23, 2019Publication date: January 9, 2020Inventors: Randall T. MOON, Mickie BHATIA, Jennifer Jean TROWBRIDGE
-
Publication number: 20170049793Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: May 1, 2015Publication date: February 23, 2017Applicants: THE GENERAL HOSPITAL CORPORATION, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20140187510Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: July 11, 2013Publication date: July 3, 2014Applicants: THE GENERAL HOSPITAL CORPORATION, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR CENTER FOR COMMERCIALIZATIONInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20140080775Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: November 18, 2013Publication date: March 20, 2014Applicants: UNIVERSITY OF WASHINGTON, The General Hospital Corporation, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20130039998Abstract: The present invention is directed to a composition comprising a modulator of the Wnt/?-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof either with a benzamide derivative or a pharmaceutically acceptable salt thereof or with a hydroxamic acid or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating bipolar disorder in a subject by administering either a benzamide derivative or a hydroxamic acid to the subject under conditions effective to treat a bipolar disorder. A modulator of the Wnt/?-catenin pathway, such as a GSK-3 inhibitor, or a pharmaceutically acceptable salt thereof may also be administered to a subject.Type: ApplicationFiled: December 23, 2009Publication date: February 14, 2013Applicants: UNIVERSITY OF WASHINGTON, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Daniel Fass, Stephen Haggarty, Edward Scolnick, Randall T. Moon, Travis L. Biechele, Nathan D. Camp
-
Patent number: 8372397Abstract: Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian subject in need thereof.Type: GrantFiled: November 30, 2010Date of Patent: February 12, 2013Assignees: University of Washington, Robarts Research InstituteInventors: Randall T. Moon, Mickie Bhatia, Jennifer Jean Trowbridge
-
Patent number: 8362216Abstract: The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G?CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described.Type: GrantFiled: October 3, 2011Date of Patent: January 29, 2013Assignees: The Johns Hopkins University School of Medicine, University of WashingtonInventors: Philip A. Beachy, Jeffrey A. Porter, Randall T. Moon
-
Publication number: 20120171779Abstract: The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G? CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described.Type: ApplicationFiled: October 3, 2011Publication date: July 5, 2012Inventors: Philip A. Beachy, Jeffrey A. Porter, Randall T. Moon
-
Publication number: 20120059021Abstract: The present disclosure relates to the regulation and function of the Wnt/?-catenin signaling pathway and the ERK signaling pathway. The disclosure provides methods of treatment for melanoma by administering both an inhibitor of ERK signaling and an activator of Wnt/?-catenin signaling. These methods may be used alone or in combination with other strategies targeting melanoma cell survival. The disclosure also provides diagnostic methods for predicting a patient's clinical response to inhibitors of ERK signaling.Type: ApplicationFiled: September 1, 2011Publication date: March 8, 2012Applicant: UNIVERSITY OF WASHINGTONInventors: Travis L. BIECHELE, Andy J. CHIEN, Randall T. MOON, Rima KULIKAUSKAS, Rachel TORONI
-
Publication number: 20120046242Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: December 21, 2009Publication date: February 23, 2012Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTONInventors: Randall T. Moon, Travis L. BIechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20120040916Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by the Wnt/?-catenin pathway by selecting a subject with a condition mediated by the Wnt/?-catenin pathway and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly inhibiting the Wnt/?-catenin pathway in a subject is also disclosed.Type: ApplicationFiled: December 21, 2009Publication date: February 16, 2012Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTONInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Patent number: 8071733Abstract: The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G?CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional fragments thereof. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described.Type: GrantFiled: May 28, 2010Date of Patent: December 6, 2011Assignees: The Johns Hopkins University School of Medicine, University of WashingtonInventors: Philip A. Beachy, Jeffrey A. Porter, Randall T. Moon
-
Publication number: 20110293750Abstract: The present invention is directed to a method of determining the prospects for survival of a melanoma patient. This method involves providing a biological sample from a patient diagnosed with melanoma, determining the level of an indicator of Wnt/?-catenin activation in the sample, comparing the level of the indicator of Wnt/?-catenin activation in the sample against a standard level of the indicator of Wnt/?-catenin activation correlated to survival of melanoma, and determining a patient's prospects for survival of melanoma based on the comparison. The present invention also relates to a method of improving survival of melanoma patients, decreasing metastases in melanoma patients, decreasing proliferation of cancer cells in melanoma patients, decreasing melanoma recurrence in melanoma patients, and/or decreasing tumor size in melanoma patients. This involves selecting melanoma patients and subsequently determining and monitoring therapy based on their level of Wnt/?-catenin activation.Type: ApplicationFiled: November 10, 2009Publication date: December 1, 2011Applicants: YALE UNIVERSITY, UNIVERSITY OF WASHINGTONInventors: Randall T. Moon, Andy J. Chien, David L. Rimm
-
Publication number: 20110251144Abstract: The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/?-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/?-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/?-catenin pathway in a subject is also discussed.Type: ApplicationFiled: September 16, 2009Publication date: October 13, 2011Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, UNIVERSITY OF WASHINGTONInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass
-
Publication number: 20110200686Abstract: The present invention is directed to a composition comprising a modulator of the Wnt/?-catenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N?-benzhydryl piperazine or a pharmaceutically acceptable salt thereof. The present invention is also directed to a method of treating a neoplastic condition in a subject by administering the modulator of the Wnt/?catenin pathway or a pharmaceutically acceptable salt thereof and an N-cinnamyl-N?-benzhydryl piperazine or a pharmaceutically acceptable salt thereof to the subject under conditions effective to treat a neoplastic disorder.Type: ApplicationFiled: April 7, 2009Publication date: August 18, 2011Applicants: UNIVERSITY OG WASHINGTON, MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Randall T. Moon, Travis L. Biechele, Nathan D. Camp, Stephen Haggarty, Daniel Fass, Andy J. Chien
-
Publication number: 20110091448Abstract: Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian subject in need thereof.Type: ApplicationFiled: November 30, 2010Publication date: April 21, 2011Applicants: UNIVERSITY OF WASHINGTON, ROBARTS RESEARCH INSTITUTEInventors: Randall T. MOON, Mickie BHATIA, Jennifer Jean TROWBRIDGE
-
Patent number: 7850960Abstract: Methods are provided for increasing stem cells, hematopoietic progenitor/stem cells, mesenchymal progenitor/stem cells, mesodermal progenitor/stem cells, muscle progenitor/stem cells, or neural progenitor/stem cells in vivo in a mammalian subject. Methods are also provided for treating an immune related disease, a mesenchymal/mesoderm degenerative disease, or a neurodegenerative disease in a mammalian subject in need thereof.Type: GrantFiled: December 30, 2004Date of Patent: December 14, 2010Assignees: University of Washington, Robarts Research InstitueInventors: Randall T. Moon, Mickie Bhatia, Jennifer Jean Trowbridge
-
Publication number: 20090047276Abstract: A method is provided for increasing the activity of adult and embryonic stem cells, progenitor cells and/or differentiated cells in vivo in a vertebrate subject. Methods are provided for increasing cell or tissue regeneration in a vertebrate subject by administering one or more Wnt/?-catenin signal-promoting agents and/or one or more inhibitors of ?-catenin-independent signaling to the vertebrate subject in need thereof.Type: ApplicationFiled: May 14, 2008Publication date: February 19, 2009Applicant: UNIVERSITY OF WASHINGTONInventors: Randall T. MOON, Cristi Lee Stoick COOPER, Gilbert WEIDINGER
-
Patent number: 7314968Abstract: The present invention is directed a Lef1/?-catenin-dependent reporter and to transgenic fish containing this reporter. The present invention is also directed to the use of the reporter and the transgenic fish as a model for the ?-catenin signaling pathway. The model is useful for identifying genes in the ?-catenin signaling pathway and for identifying drugs that can modulate the ?-catenin signaling pathway. Such drugs are useful for treating or preventing melanoma, colorectal cancer and osteoporosis, among other disease conditions.Type: GrantFiled: October 3, 2003Date of Patent: January 1, 2008Assignee: University of WashingtonInventors: Randall T. Moon, Richard I. Dorsky
-
Publication number: 20040168210Abstract: The present invention is directed a Lef1/&bgr;-catenin-dependent reporter and to transgenic fish containing this reporter. The present invention is also directed to the use of the reporter and the transgenic fish as a model for the &bgr;-catenin signaling pathway. The model is useful for identifying genes in the &bgr;-catenin signaling pathway and for identifying drugs that can modulate the &bgr;-catenin signaling pathway. Such drugs are useful for treating or preventing melanoma, colorectal cancer and osteoporosis, among other disease conditions.Type: ApplicationFiled: October 3, 2003Publication date: August 26, 2004Inventors: Randall T. Moon, Richard I. Dorsky